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Abstract
The prevalence of vitamin D deficiency in intensive care units ranges typically between 
40 and 70%. There are many reasons for being or becoming deficient in the ICU. 
Hepatic, parathyroid and renal dysfunction additionally increases the risk for developing 
vitamin D deficiency. Moreover, therapeutic interventions like fluid resuscitation, 
dialysis, surgery, extracorporeal membrane oxygenation, cardiopulmonary bypass and 
plasma exchange may significantly reduce vitamin D levels. Many observational studies 
have consistently shown an association between low vitamin D levels and poor clinical 
outcomes in critically ill adults and children, including excess mortality and morbidity 
such as acute kidney injury, acute respiratory failure, duration of mechanical ventilation 
and sepsis. It is biologically plausible that vitamin D deficiency is an important and 
modifiable contributor to poor prognosis during and after critical illness. Although 
vitamin D supplementation is inexpensive, simple and has an excellent safety profile, 
testing for and treating vitamin D deficiency is currently not routinely performed. 
Overall, less than 800 patients have been included in RCTs worldwide, but the available 
data suggest that high-dose vitamin D supplementation could be beneficial. Two large 
RCTs in Europe and the United States, together aiming to recruit >5000 patients, have 
started in 2017, and will greatly improve our knowledge in this field. This review aims to 
summarize current knowledge in this interdisciplinary topic and give an outlook on its 
highly dynamic future.
A short history of vitamin D in critical care
Only 10 years ago, a potential link between acute illness 
and vitamin D, which is well known for its role in calcium 
and bone homeostasis, was regarded as quite absurd – how 
could this hormone be acutely relevant to the specialty 
of critical care? In fact, it now transpires that the high 
prevalence of vitamin D deficiency in critically ill adults 
and children, combined with the pleiotropic effects of 
vitamin D, could indeed be of great importance in this 
patient population.
The first relevant randomized controlled trial 
was published in 2003 by the Belgian endocrinology-
anesthesiology visionary Greet van den Berge and her 
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team. In this trial, a ‘low’ dose of 200 IU of vitamin D3 
compared with a ‘high’ dose of 500 IU over 10  days in 
22 prolonged critically ill patients showed limited effects 
on inflammatory biomarkers (1). Although, in retrospect, 
the ‘high dose’ of vitamin D was quite low, this trial was 
ahead of its time and led the way revealing important 
findings of severe bone hyper-resorption and presence of 
vitamin D deficiency in the critically ill.
A few years of silence in the scientific community 
followed, but the topic rapidly regained attention after 
the publication of two studies in 2009: the report of 
high rates of vitamin D deficiency including some with 
undetectable levels among 42 Australian critically ill 
patients referred to the endocrinology department in a 
letter in the New England Journal of Medicine (2) and 
100 children requiring ICU admission for respiratory 
infections by Canadian researchers (3). This was to be 
the beginning of subsequent years of research and debate 
with skeptics arguing that deficiency is purely a bystander 
and marker of illness severity. Despite this, the current 
evidence for replacement therapy is compelling, but 
there remain unanswered questions, including adequate 
dosing strategies, the effect of critical illness on vitamin D 
metabolomics and the optimum target vitamin D level to 
provide clinical benefit in critical illness.
Vitamin D status in critically ill patients
Vitamin D deficiency is common in critical illness with 
prevalence between 40 and 70% (Table 1) (4, 5, 6, 7). In 
burn patients, the prevalence appears to be even higher 
Table 1 Selected observational trials on the incidence of vitamin D deficiency in ICU patients.
Author, Journal, Year
Design No of 
patients Vitamin D deficiency definition OutcomesPopulation
Braun A, Critical Care 
Medicine, 2011
Boston, 
Massachusetts,  
USA (5)
Retrospective 
observational study
Medical and surgical 
ICU patients
2399 Pre-admission 25(OH)D was categorized as 
deficiency in 25(OH)D (≤15 ng/mL), 
insufficiency (16–29 ng/mL) and sufficiency 
(≥30 ng/mL)
Deficiency: 27%  
(637 patients)
Insufficiency: 38% 
(918 patients)
Sufficiency: 35%  
(844 patients)
Amrein K, Critical 
Care, 2014
Graz, Austria (13)
Retrospective 
observational study
Medical and surgical 
ICU patients
655 25(OH)D was categorized as deficiency in 25(OH)
D (≤20 ng/mL), insufficiency (20–30 ng/mL), 
normal (>30 ng/mL)
Deficiency: 60% of 
patients
Insufficiency: 26% of 
patients
Normal level: 14%  
of patients
Matthews LR, 
American Journal of 
Surgery, 2012
Atlanta, USA (74)
Prospective 
observational study
Surgical ICU patients
258 25(OH)D was categorized as severe deficiency in 
25(OH)D (≤13 ng/mL), moderate deficiency 
(14–26 ng/mL) and mild deficiency (27–39 ng/mL), 
sufficiency (>40 ng/mL)
Severe deficiency: 
54% (138 patients)
Moderate deficiency: 
37% (96 patients)
Mild deficiency: 7% 
(18 patients)
Sufficiency: 1%  
(3 patients)
Venkatram S, Critical 
Care, 2011
New York, USA (75)
Retrospective study
Medical ICU patients
437 25(OH)D was categorized as deficiency in 25(OH)
D (0–19 ng/dL), insufficiency (20–29.9 ng/dL) and 
normal levels (≥30 ng/mL)
Deficiency: 78%  
(340 patients)
Insufficiency: 17%  
(74 patients)
Normal level: 5%  
(23 patients)
Higgins DM, Journal 
of Parenteral and 
Enteral Nutrition, 
2012
Ontario, Canada (76)
Prospective study
Medical and surgical 
ICU patients
196 25(OH)D was categorized as deficiency in 25(OH)
D (<12 ng/mL), insufficiency (12–24 ng/mL) and 
normal levels (>24 ng/mL)
Deficiency: 26%  
(50 patients)
Insufficiency: 56% 
(109 patients)
Normal level: 19%  
(37 patients)
Nair P, Intensive Care 
Medicine, 2015
Sydney, Australia (25)
Prospective 
multicenter cohort 
study
ICU patients
100 25(OH)D was categorized as deficiency in 25(OH)
D (<10 ng/mL), insufficiency (10–20 ng/mL) and 
normal levels (>20 ng/mL) 
Deficiency: 21%  
(21 patients)
Insufficiency: 55%  
(55 patients)
Normal level: 24%  
(24 patients)
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(8, 9). Many patients enter the ICU in a deficient state 
due to pre-existing malnutrition and disease. However, 
vitamin D metabolism is dysregulated in some critically 
ill patients with vitamin D levels rapidly falling after ICU 
admission (10, 11). The similarity between results in diverse 
geographical areas with variable UVB exposure suggests 
that the influence of individual chronic and/or acute 
disease on vitamin D deficiency is largely independent 
of sun exposure (12). A number of large observational 
studies from across the globe have confirmed that 
vitamin D deficiency (usually defined as 25(OH)D levels 
below 20 ng/mL) is frequent in adult and pediatric critical 
illness (5, 6, 13, 14, 15, 16). Vitamin D deficiency has 
been shown to be associated with sepsis, acute respiratory 
distress syndrome and acute kidney injury (17, 18, 19, 20) 
and three different meta-analyses confirm that patients 
with low vitamin D status have a longer ICU stay and 
increased morbidity and mortality (18, 21, 22). Recently, 
substantial metabolomic differences in pathways related to 
glutathione metabolism and glutamate metabolism were 
found in an observational study in vitamin D deficient 
compared to non-deficient ICU patients (separated by a 
cutoff of 15 ng/mL) (23).
In critical illness, there also is evidence of rapid falls 
in circulating 25(OH)D concentrations, potentially due 
to disrupted metabolism, fluid resuscitation, decreased 
synthesis of vitamin D-binding protein due to hepatic 
dysfunction, interstitial extravasation caused by increased 
vascular permeability, renal wasting of vitamin D, 
decreased renal conversion to 1,25(OH)D3 and increased 
tissue conversion of 25(OH)D3 to 1,25(OH)D3 (11, 24, 25, 
26). The role of free/bioavailable vitamin D remains unclear 
although it is possible that although vitamin D binding 
protein (VDBP) and thus total D decreases, circulating 
free D may be maintained (27). In a post hoc analysis of 
the VITDAL-ICU trial, free/bioavailable vitamin D was 
not superior to total 25(OH)D in predicting mortality 
neither in the placebo nor in the intervention group (28). 
There is also evidence that critically ill patients with very 
low 25(OH)D concentrations have blunted responses to 
vitamin D replacement possibly due to conversion into 
alternate metabolites and epiforms (29).
Biological rationale
There is strong biological plausibility that supports 
a contributing role of vitamin D deficiency to poor 
outcomes, mediated by genomic and non-genomic effects 
(8). In the last decade, vitamin D has been implicated in 
the function of a wide range of tissues including the innate 
and adaptive immune system (30, 31). The specific nuclear 
vitamin D receptor (VDR) is widely expressed in many cell 
types and organs relevant to critically illness (32) and is 
known to regulate hundreds of genes (32, 33). Therefore, 
vitamin D has the ability to act synergistically on the 
immune response to acute systemic inflammation and 
infection (19, 34), lung epithelial function (35), muscle 
function and metabolism (36) and cardiac function (37), 
to name a few (Fig. 1). Additional information on exact 
mechanism of action and potential influence of vitamin 
D deficiency on acute critical illness is summarized in 
Table 2.
Vitamin D, rather than a vitamin or just a food 
supplement, is therefore in reality, a precursor to a potent 
steroid hormone influencing a wide range of cellular 
pathways in organs that are highly relevant to the effects 
of critical illness and may exert its beneficial effects on 
acute inflammation, nosocomial infection, respiratory 
failure, cardiogenic shock and critical illness myopathy. 
In summary, vitamin D may help to prevent secondary 
complications in a population at very high risk and 
there is currently no rationale to suggest that, apart from 
vitamin D deficiency, any particular type of ICU patients 
could benefit more or less. However, burn patients appear 
to be at particular and even long-term risk because of the 
necessary sun avoidance after their injury (8, 9).
Bone during and after critical illness
Recently, bone health has been recognized as important 
for ICU survivors and the limited available data suggest 
impaired bone health and high fracture risk (38, 39, 40, 
41). In addition to underlying disease, critical illness per 
se seems to be detrimental to musculoskeletal health in 
various ways: immobilization, inflammation, multiple 
endocrine alterations, hypercatabolism including muscle 
wasting, malnutrition and some drugs all have the 
potential to disturb the delicate balance between bone 
formation and resorption (42, 43). In a post hoc analysis 
of the VITdAL-ICU study, vitamin D3 did not have a 
significant effect on the increased levels of β-Crosslaps 
and osteocalcin during critical illness (44). Nevertheless, 
vitamin D is one of the cornerstones of osteoporosis 
therapy. Treatment of vitamin D deficiency with the aim 
to reach levels considered necessary for optimal bone 
health in other populations (above 20 ng/mL) (45, 46) 
may possibly be the only easily adoptable treatment to 
improve skeletal consequences of prolonged critical 
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illness besides other, more expensive, risky and/or time-
consuming possibilities like antiresorptive treatment 
and physiotherapy. Hollander and Mechanick suggested 
the consideration of intravenous bisphosphonates 
which potently reduce bone resorption (47). However, 
a number of contraindications and potential side 
effects like hypocalcemia, renal impairment and atrial 
fibrillation need to be considered. In order to avoid frank 
hypocalcemia, vitamin D deficiency should always be 
treated before bisphosphonates are given. Interestingly, 
in a large retrospective analysis, patients pretreated with 
bisphosphonates had significantly better outcomes even 
though they were older; additional vitamin D seemed to 
have an additional beneficial effect (48). In summary, ICU 
survivors appear to be at high risk for excessive bone loss 
and fracture risk. Therefore, interventional studies with 
vitamin D and antiresorptive agents including denosumab 
and parenteral bisphosphonates are necessary in the near 
future.
Effects of enterally administered vitamin D  
supplementation
Van den Berghe et  al. (1) tried to demonstrate that in 
critically ill patients an intravenous supplementation with 
200 (low dose group) compared to 500 (high dose group) 
IU cholecalciferol results in elevated to normal vitamin D 
levels. Although higher levels of 25(OH)D were detected 
on days 2, 6 and 7 in the high-dose group compared to 
the low-dose group, they did not reach normal 25(OH)
D levels.
Years later, Amrein et al. (49) initiated a randomized 
controlled pilot study with an ultra-high loading dose 
vitamin D (540,000 IU) in ICU patients. In this trial, 
25 patients were randomly assigned to vitamin D3 
versus placebo. The results showed significantly elevated 
1,25(OH)D levels in the intervention group and in 80%, 
normalized 25(OH)D levels were found. In consequence of 
these results, Amrein et al. (50) initiated the VITdAL-ICU 
trial, in which 475 ICU patients with vitamin D deficiency 
(<20 ng/mL) were randomly assigned to either high-dose 
vitamin D3 or placebo. The regimen of the high-dose 
group consisted of a single high-dose supplementation 
with 540,000 IU followed by a 90,000 IU monthly 
maintenance dose for five months. The 25(OH)D level in 
the high-dose group reached sufficiency (>30 ng/mL) in 
52.2% of the patients after seven days.
Quraishi et  al. (51) compared changes of 25(OH)
D and cathelicidin levels in septic ICU patients. Thirty 
patients were randomly divided into three groups (each 
group consisting of 10 patients). The first group received 
200,000 IU cholecalciferol enterally, the second 400,000 IU 
enterally and the third a placebo. Blood was drawn on 
days 1, 3, 5 and 7. Compared to baseline, the mean change 
in total 25(OH)D in the placebo group on day 5 was 3 
(−3 to 8)%, the 200,000 IU cholecalciferol group 
Figure 1
Overview of vitamin D metabolism and its classic 
and non-classic effects on different target organs/
systems.
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49 (30–82)%, and the 400,000 IU group in 69 (55–106)% 
(P < 0.001). The bioavailable 25(OH)D increased by 
4 (−8 to 7)%, 45 (40–70)% and 96 (58–136)% (P < 0.01).
Han et al. (52) administered cholecalciferol compared 
with placebo in a double-blind, randomized controlled 
pilot study in 30 patients. Nine mechanically ventilated 
ICU patients received 50,000 IU cholecalciferol on 5 days, 
11 patients received 100,000 IU daily and 10 patients 
were given a placebo. At baseline, 13 patients (43%) had 
vitamin D deficiency (25(OH)D <20 ng/mL). The 50,000 IU 
and 100,000 IU regimens resulted in a significant increase 
in the average 25(OH)D plasma levels. On day 7, the 
values were 45.7 ± 19.6 ng/mL and 55.2 ± 14.4 ng/mL, 
respectively, compared to unchanged values in the 
placebo group (21 ± 11.2 ng/mL, P < 0.001).
Current vitamin D testing and 
supplementation in the ICU
The most common laboratory test to assess vitamin D 
nutritional status is total 25-hydroxyvitamin D serum 
concentration. There are a number of methods for 
measuring 25-hydroxyvitamin D in serum or plasma, 
including enzyme immunoassay, radioimmunoassay, 
high-performance liquid chromatography (HPLC), 
liquid chromatography–mass spectrometry (LC/MS) 
and LC/MS/MS. Laboratory professionals are often 
confronted with challenges related to vitamin D 
testing, including controversy over optimal and target 
vitamin D concentrations, variable reference ranges 
across marketed assays and reference laboratories, lack 
of standardization of vitamin D assays and misordering 
of 1,25-dihydroxyvitamin D testing. Among possible 
markers, serum total 25(OH)D is currently considered to 
be the best marker of vitamin D status (53). Measurement 
of vitamin D concentration is currently not routine 
practice on ICU and there is currently no consensus on 
definition on vitamin D deficiency, in critical illness. 
The role of other metabolites including free/bioavailable 
vitamin D remains to be clarified. Generally, progress 
has been made in the last years in the harmonization 
of various assays. However, further standardization 
(e.g. the definition of vitamin D deficiency and 
measurement of other possible markers of vitamin D 
status) would be sensible (54).
Table 2 Mechanism of action on target organ systems that may influence critically ill patients.
Target organs Mechanism of action
Immune system Vitamin D metabolites are acting as modulators of cells of the innate and adaptive system (30, 31, 34)
Innate system: 1,25-dihydroxyvitamin D3 and 3 of its analogs induce expression of the human cathelicidin 
antimicrobal peptide (CAMP) gene and genes involved in autophagy and phagosome maturation all of 
which are involved in the intracellular destruction of pathogens; promotion of an anti-inflammatory 
response by inhibiting the maturation of DCs; Adaptive system: VitD induces anti-inflammatory responses 
through direct effects on T-cells (34, 77, 78)
Cardiac function Vitamin D may play a role in atrial fibrilation prevention by negatively regulating the renin–angiotensin–
aldosterone–system (RAAS), mediating calcium homeostasis, binding to vitamin D receptors (VDR) on 
cardiac myocytes and furthermore by having antioxidant properties that may reduce levels of reactive 
oxygen species (ROS) in the atria, which contribute to inflammation and proarrhythmic substrate 
formation (79)
The exact mechanism of action unknown but the recent research on animal models suggest that calcitriol 
has been shown to have a key role in enabling the maturation and differentiation of ventricular myocytes 
isolated from neonatal rat hearts and could therefore potentially influence heart failure (37)
Vitamin D receptors are also present in all cells implicated in atherosclerosis. Those include endothelial cells, 
vascular smooth muscle cells and immune cells. It appears to regulate vascular cell growth, migration and 
differentiation; immune response modulation; cytokine expression; and inflammatory and fibrotic 
pathways. All of those mechanisms play a crucial role in different stages of the atherosclerotic plaque 
vulnerability and rupture (80)
Lung function A lack of VDRs in the pulmonary epithelial barrier appeared to compromise its defense, leading to more 
severe lipopolysaccharide (LPS)-induced lung injury. Moreover, vitamin D treatment alleviated LPS-induced 
lung injury and preserved alveolar barrier function (35). Therefore, vitamin D may be a potential 
therapeutic strategy in acute lung injury and acute respiratory distress syndrome
Muscle function 
and metabolism
Some molecular mechanism studies suggest that vitamin D impacts muscle cell differentiation, intracellular 
calcium handling, and genomic activity. Some animal models have confirmed that vitamin D deficiency and 
congenital aberrations in the vitamin D endocrine system may result in muscle weakness (36, 81, 82)
Bone Limited available data in ICU survivors suggest impaired bone health and high fracture risk (38, 39, 40, 
41, 83). 1,25(OH)(2)D(3) is known primarily as a regulator of calcium, but it also controls phosphate 
(re)absorption at the intestine and kidney. Mechanism of action involve 1,25(OH)2D3, FGF23 
(fibroblast growth factor 23 – phosphaturic hormone produced in osteoblasts) and 1,25(OH)(2)D(3) via 
the PTH axis (84)
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In the general population, it is recommended that 
all healthy children and adults meet a daily minimum 
requirement of vitamin D – the Institute of Medicine 
(IOM) recommends 400–800 IU of vitamin D3 (46). The 
Endocrine Society increased this dose to 1500–2000 IU/day 
for individuals at risk of deficiency (45, 55). Current 
standard enteral nutrition formulas used in critical 
illness contain vitamin D2 or D3 (native vitamin D, half-
life 2–3  weeks), but rarely more than 400 IU in a daily 
regimen. Parenteral multivitamin preparations typically 
contain only 200 or 220 IU of native vitamin D. In healthy 
individuals, such doses can improve vitamin D deficiency, 
but this requires months of treatment. In critical illness, 
the optimal native vitamin D dose remains unclear. 
Although no standard of care has been established, it 
appears logical that at least the recommended daily 
allowances for healthy individuals should be provided 
(400–600 IU daily for children, 600–800 IU for adults). The 
role for additional provision of active vitamin D (calcitriol 
or other metabolites) is even less clear, but certainly 
needs to be further tested. Active and native vitamin D 
metabolites are very different in half-life (several hours 
compared to a few weeks), therapeutic range (narrow vs 
broad) and costs (more expensive vs inexpensive) (56). 
There is however a biological rationale that active vitamin 
D on top of high-dose vitamin D3 could be of additional 
benefit. Besides patients with chronic preexisting renal 
dysfunction, many other ICU patients appear to be 
unable to sufficiently activate native vitamin D to its 
physiologically active form calcitriol (50). To date, no trial 
has looked at a combined vitamin D regimen.
Circulating 25(OH)D concentrations may fall rapidly 
during the initial phase of severe acute illness and its 
treatment. Therefore, the use of a loading mega-dose 
for rapid restoration of vitamin D levels followed by 
regular supplementation appears necessary in critical 
illness (57). Apart from intramuscular high-dose vitamin 
D formulations, no intravenous vitamin D mono-
preparations are available at present.
Side effects in critically ill patients
Possible side effects after high dose supplementation 
include higher risk for fractures, falls and mild 
hypercalcemia. Symptoms are mostly related to the 
effects of hypercalcemia. Vitamin D intoxication can be 
caused by high intake (>50,000 IU per day) and is typically 
linked to hypercalcemia and hyperphosphatemia. 
However, the intake of 10,000 IU vitamin D3 per day for 
up to 5 months is considered safe (58).
In ICU patients, side effects are rare and no vitamin 
D intoxication has been reported. However, due to the 
complexity of the treatment and the underlying disease, 
recognition of adverse events in a critically ill population 
is difficult. Several studies in ICU patients using mainly 
oral cholecalciferol in doses ranging from 200 IU to 
540,000 IU, reported very limited side effects (1, 50, 51, 
59, 60). In the VITDAL-ICU study, Amrein et  al. (50) 
found mild hypercalcaemia in 1% of patients, all of which 
were asymptomatic. In this trial, overall no significant 
differences in calcium, phosphorus and renal parameters 
in either group were found. Vitamin D levels in the 
treatment group were well below the level considered 
acutely toxic (150 ng/mL) (2). While outside of the ICU 
mega-doses are now obsolete because of increased fracture 
and fall risk (61), available evidence in critical illness 
from the VITdAL-ICU trial do not suggest increased risk 
for falls or fractures in these specific circumstances (50). 
Vitamin D toxicity has not been described in the ICU 
setting but may occur after prolonged intake of excessive 
doses (>10,000 IU/day and 25(OH)D levels >200 ng/mL) 
and, rarely, in individuals with mutations in CYP24A1 
causing failure to metabolize 1,25-dihydroxyvitamin D 
(62, 63). Additional information on available vitamin D 
formulations is given in Table 3.
What endocrinology can learn from intensive 
care and vice versa
Sample size and power of a study
So far, many single vitamin D intervention trials have 
given disappointing results and many more, even relatively 
large trials including the recently completed VIDA and 
awaited VITAL trial are/will likely be negative (64). A 
great issue in these studies is that despite their relatively 
large size including thousands of individuals, they still 
are underpowered. Even more problematic, they have not 
exclusively included vitamin D-deficient subjects. It is not 
reasonable why patients with normal vitamin D levels 
are included in intervention trials; moreover, vitamin D 
should ideally not be given in the placebo group (65).
Recently, this concept was beautifully discussed in a 
German epidemiologic study showing that depending on 
the baseline risk of a population, the necessary sample size 
for a single trial to have adequate power increases sharply 
in low baseline risk (66). Therefore, the high prevalence of 
vitamin D deficiency and the inherently high morbidity 
and mortality in intensive care in a short time period 
increase the probability for an intervention trial to prove 
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a beneficial effect of vitamin D. Therefore, we believe 
that currently, targeting high-risk groups and including 
exclusively patients with vitamin D deficiency will reduce 
necessary sample sizes and improve the likelihood of 
showing an effect.
Megadoses
To date, megadoses and long dosing intervals are 
considered obsolete. Besides higher risk of falls and/or 
fractures in multiple studies (61, 67), Martineau was also 
able to show a decreased efficacy of high bolus doses 
in the prevention of acute respiratory tract infections 
(68). This lack of effect appears biologically reasonable, 
as after a large dose, possibly vitamin D is catabolized 
more rapidly to inactive metabolites. Also, it is rarely 
necessary to increase vitamin D levels rapidly. However, 
in critical care, time is paramount, and vitamin D levels 
must be improved within days which is only possible 
with a megadose (57). Typical dosing regimens used in 
outpatients are ineffective in this short time period but 
a single, large vitamin D3 dose works within a few days 
(69). Therefore, the best approach in intensive care is 
probably a large loading dose followed by a regular daily 
or weekly maintenance dose. The optimal dosing regimen 
is likely also dependent on individual patient factors 
including gastrointestinal function, underlying disease, 
co-medication, renal/hepatic function, genetic factors, 
ethnicity and body weight. In critical care, it also makes 
sense to determine serial vitamin D levels to guide therapy 
in patients with prolonged ICU/hospital stay.
Vitamin D intervention trials in critical illness
In recent years, several vitamin D interventional trials with 
or without placebo groups including vitamin D-deficient 
individuals or all-comers have been completed (Table 4). 
Given the low chance of successful normalization of 
vitamin D status with the traditional daily vitamin D 
regimen (57), other supplementation strategies including 
mega-doses for initial loading have been used. Overall, 
there is substantial variation in these studies regarding 
treatment duration (single dose or up to 6  months), 
dose, route of administration (enteral, intramuscular 
or intravenous) and metabolite (native vitamin D: 
cholecalciferol, ergocalciferol, active vitamin D: calcitriol). 
With the exception of the VITdAL-ICU trial (n = 475) (50), 
these studies have been small (n < 70). In the VITdAL-ICU 
trial, there was a non-significant absolute risk reduction 
in 6-month all-cause mortality in the vitamin D group 
(placebo: 43% vs vitamin D3: 35%). The findings did 
achieve statistical significance in the subgroup with severe 
vitamin D deficiency at baseline (25(OH)D <12 ng/mL) 
corresponding to a number needed to treat of 6 (50). The 
primary endpoint, length of hospital stay, however, was 
not different between groups.
Recently, three independent groups published meta-
analyses on the effect of vitamin D on the mortality of 
ICU patients (70, 71, 72). Because of the small number of 
additional patients besides the VITdAL-ICU trial, and the 
substantial heterogeneity between studies, these meta-
analyses have added little additional information and 
maybe even caused confusion (73, 74). The conclusions 
drawn by the three groups of authors varied according 
to study selection; however, the fact that currently less 
than 800 adult patients have been included in published 
RCTs makes meta-analyses problematic at this stage. 
Furthermore, none of these trials specifically included 
critically ill patients with severe vitamin D deficiency, 
which is the only subgroup where a significant beneficial 
effect of vitamin D supplementation on mortality has been 
shown to date. Ironically, similar to other settings, vitamin D 
deficiency was not an inclusion criterion in some studies. 
Six trials are currently registered on clinicaltrials.gov 
examining the effect of vitamin D supplementation in 
critically ill patients with vitamin D deficiency. One is a 
phase 2 study in children (NCT02452762). Three trials 
involve small numbers of selected sub-groups of critically 
ill patients (e.g. acute kidney injury, NCT02962102, 
neuro-critical care, NCT02881957). A single-center study 
(n = 430) in Saudi Arabia is examining the effect of a single 
high dose (400,000 IU) of vitamin D3 in critically ill 
patients with severe deficiency (25(OH)D <12 ng/mL) with 
a primary outcome of hospital mortality (NCT02868827). 
The last two are large multi-center randomized placebo-
controlled trials that both have started in 2017 
(summarized in Table 5) and will hopefully conclusively 
answer the question if vitamin D replacement confers 
clinical benefit in critical illness.
Vitamin D intervention before critical illness
In specific circumstances including intensive 
chemotherapy in some hemato-oncologic diseases, 
cardiac and other elective surgical procedures, ICU stay is 
foreseeable. Thus, we believe that diagnosing and treating 
vitamin D deficiency (besides iron and other nutritional 
deficiencies) appears reasonable in this subgroup, but 
there are currently no data to support such an approach.
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Conclusion
Over the last decade, experimental, observational and 
clinical studies have highlighted the high prevalence 
of vitamin D deficiency, and its strong association with 
morbidity and mortality in critical illness. The scientific 
rationale as to why this may be the case is compelling. 
Supporters of vitamin D do not suggest it to be the 
panacea but this hormone plays an important pleiotropic 
role in the setting of critical illness and may support 
recovery from severe acute illness. We now have a better, 
albeit not complete understanding from clinical trials of 
the potential target vitamin D level and dosing strategies 
required for conferring benefit. Importantly, vitamin D 
Table 4 Selected prospective randomized controlled trials on the effect of oral/enteral vitamin D in adult critically ill patients.
Author, Journal, Year
Design No of 
patients Intervention OutcomesPopulation
Completed trials
Amrein K, Critical Care, 
2011
Graz, Austria (49)
RCT
Medical ICU, 
25OHD <20 ng/mL
25 1 × 540,000 IU D3, 
enteral vs placebo
Normalization of vitamin D levels in most 
patients, no adverse events; no difference in 
28-days mortality or length of stay
Amrein K, JAMA, 2014
Graz, Austria (50)
RCT
Mixed ICU, 25OHD 
<20 ng/mL
475 1 × 540,000 IU D3, 
enteral, then 
5 × 90,000 IU  
D3/month vs placebo
No difference in hospital length of stay, 
overall no significant mortality benefit, but 
large and significant mortality benefit in the 
predefined subgroup with severe vitamin D 
deficiency (25OHD) <12
Quraishi S, Critical Care 
Medicine, 2015
Boston, USA (51)
RCT
ICU, sepsis
30 1 × 200,000 IU D3, 
enteral or 
1 × 400,000 IU D3, 
enteral vs placebo
Rapid correction of vitamin D deficiency, 
increase in LL-37 compared to the placebo 
group
Han JE, Journal of Clinical 
and Translational 
Endocrinology, 2016, 
Nutrition, 2017
Atlanta, USA (52)
RCT
ICU, mechanically 
ventilated
30 5 × 50,000 IU D3, 
enteral or 
5 × 100,000 IU D3, 
enteral vs placebo
Shorter hospital stay, dose dependent 
increase of vitamin D levels and increased 
hCAP18 mRNA-expression compared to the 
placebo group
Alizadeh N, International 
Journal of Clinical 
Practice, 2016
Teheran, Iran (86)
RCT
Surgical ICU, 
stress-induced 
hyperglycemia
50 600,000 IU D3, IM vs 
placebo
25OHD levels increased significantly in the 
vitamin D group at day 7, fasting plasma 
adiponectin levels increased significantly in 
the vitamin D group, but not the placebo 
group
Miroliaee AE, Iranian 
Journal of 
Pharmaceutical 
Research, 2017
Teheran, Iran (87) 
RCT
ICU, ventilator 
associated 
pneumonia
25OHD <30 ng/mL 
46 
 
 
 
 
300,000 IU D3, IM vs 
placebo 
 
 
 
PCT levels significantly lower in the vitamin D 
group compared to placebo group, no 
significant difference in SOFA score 
between groups, mortality rate of patients 
in the vitamin D group was significantly 
lower than in the placebo group
Table 5 Comparison between the VITDALIZE and the VIOLET trial, the two ongoing, large vitamin D3 intervention trials in acute 
illness.
VITDALIZE (NCT03188796) VIOLET (NCT03096314)
Where Europe, multicenter US, multicenter
Design Double-blind, placebo-controlled RCT Double-blind, placebo-controlled RCT
Sample size 2400 (one interim analysis at 1200) 3000 (three interim analyses)
Intervention Loading dose of 540,000 IU vitamin D3 (orally, 
enteral)
Daily dose of 4000 IU vitamin D3 (orally, enteral) 
up to day 90
Single dose of 540,000 IU vitamin D3 (orally, enteral)
Inclusion criteria 25(OH)D <12 ng/mL
Admission to ICU (all-cause)
25(OH)D <20 ng/mL by point-of-care test
Acute risk factors for ARDS and mortality contributing 
directly to the need for ICU admission
Primary endpoint 28-day-mortality (all-cause) 90-day-mortality (all-cause)
Recruitment started October 2017 April 2017
Current status Recruiting, estimated completion date  
2021–2022
Stopped after first interim analysis (July 2018, ca 1400 
patients)
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0184
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 02/13/2019 11:26:00AM
via University of Birmingham and PERPETUAL ACCESS BIRMINGHAM
K Amrein et al. Vitamin D and critical illness R3137:12
testing and supplementation is readily available, safe 
and inexpensive and could be rapidly implemented into 
clinical practice if the on-going trials show benefit.
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